Literature DB >> 6477960

Modification by clofibric acid of acyl composition of glycerolipids in rat liver. Possible involvement of fatty acid chain elongation and desaturation.

Y Kawashima, A Hirose, H Kozuka.   

Abstract

Administration of p-chlorophenoxyisobutyric acid (clofibric acid) to rats induced a marked change in acyl composition of hepatic glycerolipids; a considerable increase in the proportion of octadecenoic acid (18:1) was accompanied by a marked decrease in the proportion of octadecadienoic acid (18:2). Among the glycerolipids, the changes in the proportions of 18:1 and 18:2 were the most marked in phosphatidylcholine. The change in the acyl composition of phosphatidylcholine paralleled the change in free fatty acid composition in microsomes. The treatment of rats with clofibric acid resulted in a 2.3-fold increase in activity of microsomal palmitoyl-CoA chain elongation and a 4.8-fold increase in activity of stearoyl-CoA desaturation. The activities of acyl-CoA synthetase, 1-acylglycerophosphate acyltransferase and 1-acylglycerophosphorylcholine acyltransferase in hepatic microsomes were increased approx. 3-, 1.7- and 3.6-times, respectively, by the treatment of rats with clofibric acid. These findings are discussed with respect to the role of fatty acid modification systems in the regulation of acyl composition of phosphatidylcholine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6477960     DOI: 10.1016/0005-2760(84)90184-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Sex-related differences in the enhancing effects of perfluoro-octanoic acid on stearoyl-CoA desaturase and its influence on the acyl composition of phospholipid in rat liver. Comparison with clofibric acid and tiadenol.

Authors:  Y Kawashima; N Uy-Yu; H Kozuka
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

2.  Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs.

Authors:  M Vázquez; M Alegret; M López; C Rodríguez; T Adzet; M Merlos; J C Laguna
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

3.  Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats.

Authors:  M Vázquez; S Muñoz; M Alegret; T Adzet; M Merlos; J C Laguna
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

4.  Regulation by carbohydrate and clofibric acid of palmitoyl-CoA chain elongation in the liver of rats.

Authors:  Naomi Kudo; Tomoaki Toyama; Atsushi Mitsumoto; Yoichi Kawashima
Journal:  Lipids       Date:  2003-05       Impact factor: 1.880

5.  Effects of clofibrate on lipids and fatty acids of mouse liver.

Authors:  G L Pennacchiotti; N P Rotstein; M I Aveldaño
Journal:  Lipids       Date:  1996-02       Impact factor: 1.880

6.  Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid.

Authors:  M W Wilson; L T Lay; C K Chow; H H Tai; L W Robertson; H P Glauert
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

7.  Activation of a peroxisome-proliferating catabolite of cholic acid to its CoA ester.

Authors:  T Nishimaki-Mogami; A Takahashi; Y Hayashi
Journal:  Biochem J       Date:  1993-11-15       Impact factor: 3.857

8.  Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation.

Authors:  M Alegret; E Cerqueda; R Ferrando; M Vázquez; R M Sánchez; T Adzet; M Merlos; J C Laguna
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

9.  Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression.

Authors:  C W Miller; J M Ntambi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Chiral inversion of (R)-(-)-fenoprofen in guinea-pigs pretreated with clofibrate.

Authors:  M F San Martín; A Soraci; F Fogel; O Tapia; S Islas
Journal:  Vet Res Commun       Date:  2002-06       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.